Description: Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, diagnostics, and others. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastroprokine products; and Anderson-Fabry and Serotonin-agonist antianxiety drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, and seasonings, such as soups or bouillons; and chemical product materials consisting of pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, primarily dogs and cats; and cattle, swine, poultry, horses, and aquacultured fish. Additionally, the company provides point-of-care testing diagnostic products for infectious diseases comprising influenza, streptococcus, etc., as well as acute myocardial infarction; diagnostics to measure bone and calcium metabolism markers, and drug concentration levels in the blood; high sensitivity products combining small immunofluorescence analyzers and special reagents; and authorized generic pharmaceuticals. Sumitomo Dainippon Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application (CiRA); Kyoto University; and Aikomi, Ltd., as well as a joint development agreement with SanBio, Inc. The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. Sumitomo Dainippon Pharma Co., Ltd. was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Dainippon Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
Home Page: www.sumitomo-pharma.com
6-8, Doshomachi 2-chome
Osaka,
541-0045
Japan
Phone:
81 6 6203 5321
Officers
| Name | Title |
|---|---|
| Mr. Hiroshi Nomura | CEO, Pres & Representative Director |
| Hisayoshi Kashima | Sr. Director & Corp. Controller |
| Mr. Naoki Noguchi | Exec. Officer of Corp. Governance, Corp. Communications & Sr. Director of Corp. Governance |
| Mr. Takuya Taguchi | Sr. Exec. Officer & Exe. Director - Sales & Mktg Div. and Deputy Head of Japan Bus. Unit |
| Ms. Atsuko Higuchi | Sr.. Exec. Officer of External Affairs, Corp. Secretariat & HR |
| Mr. Yoshiharu Ikeda Ph.D. | Sr. Exe. Officer of Cancer, Modality & Drug Research Div., Head of Japan Busi Unit and Director |
| Mr. Hiroyuki Baba | Sr. Exe Off. of Global Data Design, Legal Affairs. IP, IT Mgt, & Frontier Bus. Off. and Director |
| Mr. Toru Kimura Ph.D. | EVP of Global Corp. Strategy, Regenerative & Cellular Medicine Off. and Representative Director |
| Dr. Shigeyuki Nishinaka Ph.D. | Sr. Exe. Officer of Global Bus. Dev. & International Bus. Management and Director |
| Mr. Hideyuki Harada | Sr. Exec. Officer of Tech. Research & Dev. Div., Mfg. Div., Deputy Head of Japan Bus. Unit |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 19.4553 |
|---|---|
| Trailing PE: | 30.8333 |
| Price-to-Book MRQ: | 0.6426 |
| Price-to-Sales TTM: | 0.0053 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 6987 |